Figure 5.

Iba‐1 immunofluorescence analysis (panel A), including representative images (panel B; scale bar = 200 μm), in the ventral horn (indicated in the graphical scheme) of the lumbar spinal cord of male TDP‐43 (A315T) transgenic and wild‐type male mice after the daily treatment with WIN55,212‐2 (5 mg·kg⁻¹), in the absence or presence of the selective CB₁ receptor antagonist rimonabant (5 mg·kg⁻¹) or the selective CB₂ receptor antagonist AM630 (5 mg·kg⁻¹), or vehicle, from day 65 up to day 90 after birth. Values are means ± SEM of 10 animals per group. Data were assessed by one‐way ANOVA followed by the Bonferroni test [*P < 0.05 vs. wild type; @P < 0.05 vs. TDP‐43 (A315T) transgenic mice treated with WIN55,212‐2 and AM630].